Cell Therapeutics Inc. announced it will spin out Aequus BioPharma Inc. to commercialize its Genetic Polymer technology, which was developed to optimize half-lives of biologics for optimal dosing. Although the company believes it can modify marketed compounds without infringement, it also thinks the resulting products will be similar enough to pursue biosimilar status.

That said, Aequus will initially focus on developing longer-acting versions of biotherapeutics that are coming off patent.